Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 240.
AMIPAQUE vs OMNIPAQUE 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Iodinated radiocontrast agent that attenuates X-rays due to high atomic number of iodine, enhancing vascular and tissue contrast during imaging procedures. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
Intravenous administration: 50-200 mL (12-48 g iodine) of OMNIPAQUE 240 (240 mg iodine/mL) as a single dose, adjusted for procedure and patient size.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
Terminal half-life approximately 1-2 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Primarily renal (glomerular filtration, no tubular reabsorption); >95% excreted unchanged in urine within 24 hours; <5% biliary/fecal
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent